(a)
(b)
(c)
Figure 1: The number (left panels, N) and incidence (right panels, %) of patients who developed adverse events leading to a change in treatment including peripheral neuropathy (top row, N = 250), haematological toxicity (middle row, N = 267), and gastrointestinal toxicity (bottom row, N = 229).